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Abstract
Background: The role of consent for research use of health information is contentious. Most discussion has
focused on when project-specific consent may be waived but, recently, a broader range of consent options has
been entertained, including broad opt-in for multiple studies with restrictions and notification with opt-out. We
sought to elicit public values in this matter and to work toward an agreement about a common approach to
consent for use of personal information for health research through deliberative public dialogues.
Methods: We conducted seven day-long public dialogues, involving 98 participants across Canada. Immediately
before and after each dialogue, participants completed a fixed-response questionnaire rating individuals' support
for 3 approaches to consent in the abstract and their consent choices for 5 health research scenarios using
personal information. They also rated how confident different safeguards made them feel that their information
was being used responsibly.
Results: Broad opt-in consent for use of personal information garnered the greatest support in the abstract.
When presented with specific research scenarios, no one approach to consent predominated. When profit was
introduced into the scenarios, consent choices shifted toward greater control over use. Despite lively and
constructive dialogues, and considerable shifting in opinion at the individual level, at the end of the day, there was
no substantive aggregate movement in opinion. Personal controls were among the most commonly cited
approaches to improving people's confidence in the responsible use of their information for research.
Conclusion: Because no one approach to consent satisfied even a simple majority of dialogue participants and
the importance placed on personal controls, a mechanism should be developed for documenting consent choice
for different types of research, including ways for individuals to check who has accessed their medical record for
purposes other than clinical care. This could be done, for example, through a web-based patient portal to their
electronic health record. Researchers and policy makers should continue to engage the public to promote greater
public understanding of the research process and to look for feasible alternatives to existing approaches to
project-specific consent for observational research.
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Background
Internationally, the secondary use of existing personal
health information for research purposes is intensifying.
While administrative datasets continue to have an impor-
tant role in a variety of health research, increasingly
researchers are turning to clinical records, as they become
available in electronic format. These clinical records pro-
vide a much richer source of data than is available through
administrative records. In addition, registries are being
developed in many academic healthcare facilities to serve
as data sources for a variety of future research needs.
The role of consent in the secondary use of health infor-
mation for a variety of types of observational research
involving the health record has been particularly conten-
tious. Until recently, the policy discussion has focused on
the circumstances under which a particular research pro-
tocol would be exempted from obtaining individual con-
sent. More recent discussions have acknowledged a
broader range of consent options involving: [1]
- opting-in (project-specific or a broad authorization for
research use);
- opting-out (usually with some notification process); or
- use without the option of opting out.
The views of the public in this matter have been sought in
several different countries and have been summarized in
a previous paper [2]. Briefly, public attitudes on the need
for and type of consent for research use of their health
information are context-specific. Factors that influence
consent choice include: the identifiability of the data
[3,4]; whether there is any commercial element to the
research [2]; the type of information being accessed [5];
and the trust that the information will be kept confiden-
tial [6].
In 2005, we surveyed the Canadian public on a spectrum
of alternatives to conventional project-specific consent for
research use of personal information, including: no use at
all, prior individual consent for each use, prior broad
authorization for different types of uses, notification with
an opportunity to opt-out, and use without consent or
notification. Findings indicated that the public values
both privacy and health research and would be concerned
if either of these impinged upon the other. The majority
of the public was open to alternatives to conventional
project-specific consent; however, there was no clear pre-
ferred approach to consent for use of personal informa-
tion for health research [2].
Recognizing this is a complex and challenging topic, in
the spring of 2005, we conducted a series of structured
public dialogues across Canada as an alternative method
to elicit public values and to work toward an agreement
about a common approach to consent for research use of
personal information. Public dialogues differ from focus
groups. Focus groups are commonly used to gain richer
insight into the reasons behind particular attitudes toward
a product, service, or a concept. By contrast, public dia-
logues seek to find agreement on fundamental values-
based choices and substantial consensus for policy direc-
tions [7]. While differences are neither suppressed nor
ignored, there is a deliberate choice to build on the com-
mon ground rather than focus on differences. This paper
presents findings from these dialogues and compares
them with the findings from the public opinion survey to
draw further insights about the nature of public values
surrounding this topic and the ability to seek consensus
regarding future policy directions.
Methods
Recruitment for dialogues
We convened seven day-long public dialogues: two in
Vancouver, British Columbia, and in Montreal, Quebec,
and one each in Hamilton, Ontario, Toronto, Ontario,
and Halifax, Nova Scotia. We chose these cities to obtain
broad regional representation from across Canada. Five of
the dialogues were held in English and two in French. Par-
ticipants in two of the dialogues were recruited through an
invitation at the end of a public opinion survey of 1230
Canadians that we had conducted on the topic of privacy
and access to personal information for health research [2].
The remainder were recruited through random-digit dial-
ling within the vicinity of the target cities, by the Institute
for Social Research, York University. Dialogue partici-
pants were provided an honorarium of $50. During
recruitment, these participants were administered a small
subset of questions from the original survey to determine
comparability of this sample to the sample that partici-
pated in the full survey, with regard to socio-demograph-
ics and opinion on general attitudes toward privacy and
health research.
Background workbook
One week before the dialogues, participants received a
workbook containing background information to facili-
tate an informed conversation. The workbook presented
three general approaches to the role of consent in the use
of personal information for health research as a starting
point for their discussion:
- Approach 1: consent for each research use. This approach
maximized individual choice. It also most closely reflects
the current default assumption for secondary use of per-
sonal information generally: consent obtained in advance
for a very specific use of the information.BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
Page 3 of 13
(page number not for citation purposes)
- Approach 2: not requiring consent for research use of
their information (called "assumed consent" in the dia-
logues). This approach maximized efficiency of research
and represents the way information from the medical
record has been used historically for quality improve-
ment/system management, and for medical education.
Participants were told there would be a notification sys-
tem that one's information was being used for research
purposes, with an option to opt-out of research use, but
the onus was on the individual to do so.
- Approach 3: broad authorization for a range of future
research uses, determined by the individual (called
"broad consent" during the dialogues). Under approach 3,
the individual opted into research use of their informa-
tion, but authorization extended beyond individual
projects, and allowed for excluding certain types of uses,
and for future changing of one's consent choices in the
future or withdrawing permission entirely.
The workbook presented arguments for and against each
approach, without reference to any particular disease or
application. For all research uses, the operating assump-
tion was that all directly identifying information would be
removed prior to use. Participants were advised that this
would make it difficult, though not impossible, to re-
identify individuals.
The dialogues
The dialogues were carried out by the Canadian Policy
Research Networks, using an adaptation of the method of
Yankelovich [8]. The dialogues ran approximately six
hours on either a Saturday or Sunday. The general
approach was to have introductory material in a plenary
session, with breakouts into smaller groups to deliberate
on specific issues, followed by a plenary where each group
presented a summary of its deliberations. In three dia-
logues, the number of participants was small enough that
they did not break out into smaller groups for delibera-
tions. All plenary sessions were audio recorded digitally
and note-takers were assigned for the small group deliber-
ations. At least one study co-investigator attended each of
the sessions as a listener and a resource person, in the
event there was a need for clarification over technical
issues.
The first breakout session examined each of the three con-
sent approaches in the abstract – i.e. independent of any
specific disease, type of information, or type of research.
Participants voiced what was desirable and any concerns
with each approach. In the second, participants discussed
their consent preference in three scenarios: (i) linking
their health information with non-health information
such as education and income levels; (ii) linking their
health information with biological material and (iii)
using their health information for commercial purposes.
This was followed by a plenary discussion of how partici-
pant's consent preferences would change with each of the
scenarios. Finally, participants broke into triads to discuss
several possible safeguards and the impact these would
have on their confidence that their information was being
used responsibly. They then re-convened to discuss these
in the larger group.
Eliciting of consent choices
Prior to and immediately following the dialogues, partic-
ipants completed a questionnaire (see Additional files 1
and 2) where they rated their level of support for each of
the three general approaches to use of personal informa-
tion for research, using a 7-point rating scale that varied
from "dislike very much" to "like very much". They also
indicated their consent choice for five different scenarios
involving personal information for observational health
research:
1. Research that tracks how doctors prescribe medications
to give them feedback to help them improve the care they
provide;
2. Research that tracks how doctors prescribe medications
so drug companies can better target their advertising to
doctors;
3. Research that looks at the relationship between health
and work, education or income. To do this, information
about work, education or income must be combined with
information from the health record; and
4. Research that studies leftover tissue following surgery to
better understand the cause of the disease – linking age,
sex, diagnosis, and other medical conditions with the
sample:
4.1. If the researchers have no plans to develop a commer-
cial product, like a lab test, that is sold for profit
4.2. If the goal of the research is to identify a new test that
could better diagnose if you had a condition that needed
the surgery. The lab test would be sold for profit.
For each of the five scenarios above, consent options
expanded on the three general approaches to include:
- My information should not be used for this purpose.
- My permission is needed each time before my informa-
tion is used. (Approach 1)BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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- My general permission is needed. This could be for sev-
eral different research studies. (Approach 3 – broad con-
sent)
- My permission is not needed, but I want to know this is
being done. (Approach 2 – assumed consent)
- There is no need for me to know. Just use it.
The first and last options gave the participants the oppor-
tunity to express an opinion that was either more restric-
tive or more permissive than the alternatives that we
presented in the abstract discussion of consent
approaches. Thus, response options were comprehensive
and unconstrained by the three general approaches pre-
sented.
In the questionnaire administered immediately post-dia-
logue, participants were asked what would be the effect of
a range of procedural and technical safeguards on their
confidence that their information was being used respon-
sibly. Then, they were asked to identify their consent
choices for the same five scenarios presented in the pre-
dialogue survey, assuming their top three safeguards were
in place, and any other conditions they felt were neces-
sary.
Analyses
We tabulated participants' attitudes toward the three gen-
eral consent approaches to using personal information for
research. The 7-point scale was transformed, so that
"strongly dislike" equalled "-3", a neutral opinion
equalled "zero", and "strongly like" equalled "3". We
tested the significance of the change in scores between
pre- and post-dialogue using a parametric test (paired t-
test) and used a non-parametric test (signed rank) to
assess the robustness of the results. The criterion for statis-
tical significance was set at alpha = 0.05 adjusted for mul-
tiple analyses using the Bonferroni method. All analyses
were performed using SAS 9.1 (Cary, NC). As findings
were equivalent, we report only the parametric statistics.
We also examined what percent of participants changed
their responses in the post-dialogue survey. We tested for
any change between the post-dialogue and the pre-dia-
logue surveys and for a directional change in attitude from
positive to negative or from negative to positive. Similarly,
we tabulated consent choices across the 5 research scenar-
ios and tested for changes in consent choices using paired
t-test with signed rank test used to test the robustness of
the results. We tested for differences pre-and post-dia-
logue between dialogue groups using Analysis of Variance
(ANOVA) and Multivariate Analysis of Variance
(MANOVA). We also inspected the patterns of responses
using graphical techniques. Finally, we tabulated and
ranked the proposed safeguards.
Transcripts from the dialogue had been coded for the pur-
poses of writing up a report on the dialogues [9]. For this
paper, we sought illustrative quotes that could inform the
key findings from our quantitative analyses. To this end,
codes related to the key themes derived from the quanti-
tative analysis were reviewed by two members of the team
and quotes were selected to provide more contextual
information and insight into the meaning of the key
themes regarding consent choices.
Results
In total, 98 people took part in the dialogues. Participants
were similar in age to the general population, but had a
higher level of education and were more heavily repre-
sented by women (59% vs. 51%) than the general popu-
lation. (Table 1) On ten key survey questions, dialogue
participants who were drawn from the full survey (n = 21/
98) expressed views that were somewhat more research
friendly and less privacy concerned than the survey sam-
ple from which they were drawn. Attitudes toward privacy
and health research were equivalent among source popu-
lations – i.e. those who completed the full telephone sur-
vey and those who answered the short telephone survey.
(see Additional file 3)
Attitudes toward the three consent approaches in the 
abstract
Figure 1 compares participants' attitudes toward each of
the three general approaches to consent for research use of
one's personal information. Across the three approaches,
broad consent (Approach 3) was regarded the most
favourably, both pre- and post-dialogue. For Approaches
1 (consent for each use) and 2 (assumed consent), atti-
tudes were almost evenly distributed across the spectrum
– from extremely positive to extremely negative. For
Approach 3 (broad consent), attitudes were skewed
toward the positive.
Following the dialogue, participants generally rated all
three approaches to consent somewhat lower. Only for
broad consent did the change in rating approach statisti-
cal significance – and only when using the paired t-test
prior to adjusting for multiple testing. (Table 2)
While there was shifting in response in approximately
55% of participants, an inflection in opinion (i.e. a
change from a positive to a negative sentiment or vice-
versa) occurred infrequently (8–23%), and was most sta-
ble for broad consent (92% no change). Our tests revealed
no differences between dialogue groups in changes in rat-
ings pre- vs. post-dialogue.
Participants generally liked certain aspects of each consent
approach and disliked other aspects. From the discus-
sions, the most frequently mentioned desirable feature ofBMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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Table 1: Participant demographics and comparison with general population
Category Number of Participants (n = 98) Participants (%)* General Population+ (%)*
Sex
Female 58 59 51
Age
20–39 37 38 37
40–59 35 36 39
≥ 60 26 27 23
Highest Level of Education
High school or less 26 26 44
Some post-secondary 18 18.7 10
Completed post-secondary 42 42.7 41
Post graduate or professional degree 12 12.5 5
Other Categories
Visible Minority 14 14 13
Aboriginal 2 2 4
Disabled 11 11 5
* Percentages may not add up to 100, due to rounding
+ Total population demographic data: 2001 Census, Statistics Canada.
Comparison of Pre-Post Dialogue Ratings of Different Approaches to Consent Figure 1
Comparison of Pre-Post Dialogue Ratings of Different Approaches to Consent.BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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Approach 1 (consent for each use) was the opportunity
for knowledge and communication that this approach
facilitated – not just for purposes of control but also to
better appreciate their contribution to the research.
"I like the idea that you would be given information
about the specific research project because that gives
you a sense of contributing to the community and
what is needed for health care and it gives you a sense
of, of being part of the picture without sacrificing your
individual privacy." (Female, Toronto)
Participants also found Approach 1 to be particularly
respectful of individuals.
" [It] was respectful I heard in two ways: One is
because there's more awareness, but also it's the one
that respects privacy the most was, was what several
people said. So respectful of the information and in
terms of knowing more how it would be used, but also
respectful of the person's privacy." (Female, Vancou-
ver)
At the same time, participants recognized that this
approach is particularly burdensome for both researchers
and for those whose data were to be used. They also rec-
ognized the increased potential for sampling biases using
this approach.
Approach 2 (assumed consent) was recognized by partic-
ipants as the most efficient approach and the least likely
to produce biased results.
"There's a lot more incentive to do research, whereas
the first approach would be very cost intensive and
labour intensive." (Male, Toronto)
"I should think the research would be more, could be
more accurate because they would have a wide group
of people and most people aren't going to opt out."
(Female, Toronto)
They also recognized the considerably reduced burden on
the individuals whose consent would otherwise be
sought. However, participants expressed concern over the
onus placed on individuals if they wished not to partici-
pate.
"I think the, the less well or sicker individuals in the
population just don't have the time or energy to con-
sider becoming aware of things like opting out."
(Female, Toronto)
They also expressed concern over the relative lack of indi-
vidual knowledge or control under this approach, and the
high potential for abuse.
"Is it really OK to just broadly take people's informa-
tion without them being aware of it? And because of
that, there is definitely room for abuse. I mean one
would hope that that wouldn't happen but, you know,
unfortunately there are abuse situations that do hap-
pen." (Female, Vancouver)
Approach 3 (broad consent) was seen by many to be a
compromise between Approach 1 and Approach 2. It was
seen to be less burdensome than Approach 1 but, as an opt
in approach, it offered greater control than did Approach
2, and periodic renewal of their boundary setting.
"We liked this because we can change and set our own
boundaries... and that can happen presumably at any
stage in the, in the process." (Female, Vancouver)
The chief concern was how such a system of broad author-
ization might work.
The ability for individuals to maintain control was an
important theme. Particularly in Approach 2 (assumed
consent), participants emphasized the importance of hav-
ing the opportunity to opt-out. However, regardless of the
approach or the stated ability to opt-out at some future
point, participants expressed concern over what might
become of the data once released to the researcher.
[Approach 1 – consent for each use] "I don't think
it's workable for the common good. You see, and the
other issue raised with a central information gathering
Table 2: Testing post-pre difference of approaches
Approach Mean (SD) Pre* Post* Post minus Pre P-value for difference (paired t-test)**
1. Consent for each use Mean (SD) 0.34 (1.95) 0.14 (2.07) -0.21 (2.02) 0.315 (df = 95***)
2. Assumed consent Mean (SD) 0.44 (1.99) 0.18 (2.10) -0.29 (1.82) 0.122 (df = 96)
3. Broad Consent Mean (SD) 1.55 (1.64) 1.21 (1.55) -0.32 (1.54) 0.048 (df = 94)
* 7 Point scale where 3 = strongly like, 0 = neutral, & 3 = strongly dislike
** Bonferroni correction: Alpha = 0.017 (0.05/3)
*** df: Degree of freedom;BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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agency, you see it's open to anybody in the end. If you
have enough money, if you throw enough money on
it anybody can get your information once it is assem-
bled in that type of fashion." (Male, Vancouver)
[Approach 2 – assumed consent] "Not being able to
effectively opt out 'cause once you're in, how do you
get the information back, it's already out the door?
Like getting the cows back after they've left the barn."
(Male, Vancouver)
[Approach 3 – broad consent] "... once you jot down,
you check in this corner that it's OK to view your med-
ical records or whatever it is, that broad consent, I
mean I worked in a hospital with medical records,
they, that can go all over the place and all the research-
ers do is they say 'Oh look, he checked that so we can
do whatever we want.' and that's exactly what they do
because they want to make it easier for themselves,
understandably. We always want to get the, the red
tape out of the way, and once that one consent is given
then they can do this, this and this and this and
nobody can stop them." (Male, Toronto)
Consent choices for specific scenarios
Figure 2 and Table 3 summarize participants' consent
choices for each of the five scenarios. Across all scenarios,
the response profile, in aggregate, was not substantively or
statistically different pre- vs. post-dialogue. Consequently,
we quote post-dialogue numbers in the following para-
graphs. At the individual level, for all but one scenario,
close to half of participants shifted their consent choice
between the pre- and post-dialogue surveys. (Table 4)
Shifting of response occurred approximately equally in
both directions. The one exception was use of prescribing
information for market research. Here, fewer individuals
altered their response in the post-dialogue survey. Again,
our tests revealed no differences between dialogue groups
in changes in ratings pre- vs. post-dialogue.
Use of prescribing information for quality improve-
ment  yielded the most permissive response profile.
Almost half of all participants opted for a passive process
of either using the data without notification (21%) or
notification with opt-out (27%). One-fifth opted for a
broad consent and about 1/4 preferred their permission
be sought for each use.
Use of prescribing information for marketing research
yielded the most restrictive response profile. Almost 60%
of respondents felt their information should not be used
for this purpose at all. Another 14% felt their permission
should be sought every time. Only 18% opted for a pas-
sive process of use without notification (5%) or notifica-
tion with opt-out (13%).
Linking work, education, or income with people's
health information. Opinions here covered the full spec-
trum of consent alternatives. About 10% felt this informa-
tion should not be linked at all. About 1/4 preferred their
permission be sought for each use. About 1/3 opted for
broad consent and another 1/3 for a passive process of use
without notification or notification and opt-out (17%
each).
Linking individuals' health information with leftover
tissue for non-commercial purposes showed a very simi-
lar response profile to the linkage with work, education,
or income data. When linkage with leftover tissue
involved development of a product for profit, consent
choices became more restrictive, with the majority of peo-
ple calling for either permission for each use (45%) or no
such linkage at all (18%) with their information.
Safeguards and Controls on Disclosure
Most of the 9 safeguards and controls identified in the
post-dialogue survey either moderately or greatly
increased people's confidence that their information
would be used responsibly for research. When asked to
identify the top three safeguards or controls, four stood
Table 3: Testing post-pre dialogue change in consent choices across the five scenarios*
Scenario Pre-Dialogue** Post-Dialogue** Difference P-value for difference
(paired t-test), df = 78 ***
A) Prescribing information for improving care Mean (SD) 3.49 (1.08) 3.29 (1.25) -0.21 (1.07) 0.096
B) Prescribing information for marketing research Mean (SD) 1.99 (1.20) 1.94 (1.29) -0.03 (0.88) 0.798
C) Linking work, education or income to individual's 
health record
Mean (SD) 2.79 (1.36) 3.03 (1.24) 0.19 (1.03) 0.104
D1) Linking individual's information with leftover tissue 
with no commercial use
Mean (SD) 3.18 (1.23) 3.06 (1.25) -0.17 (1.27) 0.251
D2) Linking individual's information with leftover tissue 
with possible commercial use
Mean (SD) 2.31 (1.10) 2.40 (1.05) 0.06 (1.06) 0.595
* Due to an error in the Hamilton survey, the full consent scale was not offered. The option "Do not use" was not offered.
** Scores: 1 = do not use; 2 = consent for each use; 3 = broad authorization; 4 = notification with opt-out; 5 = use without notification;
*** Bonferroni correction: Alpha = 0.01 (0.05/5)BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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out above the others: (1) fines and penalties for breaking
rules; (2) the ability to say 'No' to use for certain types of
research; (3) the ability to check who has used your health
information; and (4) safeguards like passwords. (Figure 3)
Four of the five safeguards less often identified in the top
three choices consisted of third-party controls over use of
the information, including the existence of a provincial
privacy commissioner, an institutional privacy officer,
review of the proposed research by a research ethics board
(REB), and review by a group of people who may be
affected by the research. There was considerable discus-
sion of REBs in particular, as they figured prominently in
the workbook under each of the three general approaches
to consent. Prior to the dialogues, most participants were
unaware of the existence of REBs. While there were gener-
ally positive sentiments toward REBs, in several of the dia-
logues, concern was raised by some individuals that the
REBs may over-ride their wishes to maintain control over
use of their information.
Table 4: Percentage of Participants who changed their responses to the five scenarios
Scenario Change
More restrictive
[x/n (%)]
No change
[x/n (%)]
More permissive
[x/n (%)]
A) Prescribing information for improving care 22/78 (28.21) 42/78 (53.85) 14/78 (17.95)
B) Prescribing information for marketing research 13/78 (16.78) 52/78 (66.67) 13/78 (16.78)
C) Linking work, education or income to individual's health record 16/78 (20.51) 39/78 (50.00) 23/78 (29.49)
D1) Linking individual's information with leftover tissue for non commercial product 
development
23/78 (29.49) 37/78 (47.44) 18/78 (23.08)
D2) Linking individual's information with leftover tissue for profitable product development 15/78 (19.23) 39/78 (50.00) 24/78 (30.77)
* Excluding Hamilton survey, for which the full consent scale was not offered.
Figure 2 Pre and post-dialogue consent choices across research scenarios Figure 2
Figure 2 Pre and post-dialogue consent choices across research scenarios.BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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There should be well-defined policies that guide the,
the REB – especially if, if they're going to overturn
what the individual consent, I mean the person who
says "Well, we don't consent." and the REB says "Well,
you know, go ahead anyways." There should be spe-
cific policies. (Male, Halifax)
But I think the way he put it was that there's a really big
hole in, in the process. And that's the override that, in
some situations, the researchers could simply – well, I
shouldn't say "simply" 'cause they'd have to go
through an REB – but they could decide to use infor-
mation without, without actually having us as individ-
uals give permission for it. (Female, Toronto)
These sentiments may have arisen in response to a state-
ment in the workbook explaining that, under Approach 1
(consent for each project), an REB can permit the
researcher to use personal health information without
individual consent, so long as certain established condi-
tions were met.
Discussion and conclusion
Dialogue participants were supportive but not passive
Overall, dialogue participants were very supportive of
their de-identified health information being used for
research. However, most do not wish to entirely let go of
their ability to control use of their personal health infor-
mation for research, even if direct identifiers are removed.
Top-ranked safeguards and controls Figure 3
Top-ranked safeguards and controls.
Question: “From the list below, what are the top three things that would increase your confidence 
that your information was being used responsibly for health research?” BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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This is consistent with our earlier survey of the Canadian
population and survey and focus group work in other
countries [2,6,10-13]. In addition, we learned from the
dialogues that members of the public are sensitive to the
practical implications of requiring consent – including the
additional costs and the biases that can be introduced
through an opt-in consent regime – and would not want
to see this impede research. Some also see the consent
process as more than an issue of control, viewing it also as
an opportunity to see how their information was contrib-
uting to the public benefits that may ensue from research.
This certainly reinforces the concept of consent as a trans-
action [14].
No dominant consent choice emerged... with the 
exception of market research
We examined three general approaches to consent for
research use of de-identified health information in the
abstract and then considered specific scenarios with a full
range of consent options. In the abstract, broad consent to
a range of research was clearly preferred over project-spe-
cific consent or assumed consent. Based on this, one
might have expected broad authorization to be a clear
favourite when specific scenarios were presented. How-
ever, no more than 30% of dialogue participants chose
this option under any of the five scenarios presented.
Indeed, no dominant consent choice emerged across the
scenarios presented with one exception. Over half of dia-
logue participants (57%) felt their de-identified health
information should not be used at all for marketing
research (Scenario 2). This contrasts with laws in most
jurisdictions internationally that permit commercial use
of "anonymous" information and the common practice,
globally, of compiling de-identified prescription data to
ascertain physician prescribing patterns for marketing
purposes [15].
Even in the presence of a clear public benefit (Figure 2,
Scenarios 4a and 4b), the presence of some element of
profit, resulted in a shift toward greater control over use of
that information. When profit was introduced into the
scenario, the percent of participants supporting use of the
information without notification dropped substantially
from 18% to 4% and the percent requiring project-specific
consent grew from 32% to 44%. Further, those saying this
information should not be used at all increased from 8%
to 18%. While the response profile for this scenario was
less restrictive than that observed for the pure marketing
scenario, it still presents a challenge for research policy. It
has been recognized that conventional project-specific
consent for research using DNA databanks would render
such research impracticable [16]. Much of this research is
funded by the private sector and commercialization of
discoveries made in the course of publicly funded research
is strongly encouraged [17-19]. A more nuanced discus-
sion over commercial interests in health research is war-
ranted in future dialogues.
Participants preferred personal controls
As for safeguards and controls, we note with interest that
personal controls – consent and the ability to audit who
has accessed one's information – were among the most
commonly cited approaches that that improved people's
confidence in the responsible use of their information for
research. Third-party controls – e.g. research ethics boards,
privacy officers, privacy commissioners, and panels of
affected individuals – were nominated less often. In part,
this may be due to lack of familiarity with these mecha-
nisms. Yet, these mechanisms are key safeguards in our
current system. In particular, research ethics boards have
wide discretionary power to exempt specific research
activities from requiring consent and the conditions
under which this may occur. We note as well, regardless of
consent regime, the high level of concern that was voiced
over what happens to one's personal information once it
is released to researchers.
Limitations
We recruited our dialogue participants through random-
digit dialling by an academically based polling firm.
Twenty-one participants were recruited after completing a
comprehensive attitude survey. The other 75 were asked a
few general questions about health information privacy
and about research use of their information. Our inten-
tion was to see if the dialogue process would be any differ-
ent in groups that had an opportunity for prior
consideration of this issue through the survey. Unfortu-
nately, we were unable to recruit enough people from
among those who participated in the full survey to allow
this comparison. Indeed, participation rates in the dia-
logues were very low (approximately 2% of those com-
pleting the long survey and 4% of those completing the
short survey). This raises the question of selection bias
among dialogue participants. We noted earlier that partic-
ipants had a higher level of education and were more
heavily represented by women than the general popula-
tion. Based on the common questions asked in both sur-
veys, we were able to ascertain that dialogue participants
were somewhat more research friendly and less privacy
concerned than the population from which they were
drawn. However, these differences were small.
Most public dialogues are associated with movement in
position on the issue at hand by end of day [7,20]. In our
dialogues, we saw little movement in opinion in aggre-
gate. One may question whether this represents some fail-
ure of the dialogue process. We think not. Across all seven
dialogue sessions, discussions were lively and construc-
tive, displaying a spirit of mutual understanding. In addi-BMC Medical Ethics 2008, 9:18 http://www.biomedcentral.com/1472-6939/9/18
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tion, there was substantial movement in opinion at the
individual level between the beginning and the end of the
day-long dialogues (Tables 4 and 5). It seems the same
evidence moved some individuals toward a more restric-
tive approach to use of their information for research and
others toward a more permissive use. Based on this, we
feel it is reasonable to conclude that we succeeded in
being even-handed in the presentation of the issues at
hand – or that our dialogue participants were sufficiently
independent thinkers. In addition, our observation of lit-
tle movement in aggregate is, in large part, consistent with
findings from a recent public dialogue on the topic of
biobanks in British Columbia [21].
Policy implications
No one approach to consent satisfied even a simple
majority of dialogue participants. Given this, as Canada
moves toward developing a common inter-operable
health record, consideration needs to be given to develop-
ing a system for a mechanism for documenting individu-
als' consent choices for research and other secondary uses
of their personal health information, embracing a broader
array of consent options than the current dichotomous
alternatives of project-specific consent or exemption from
consent. Given the high importance participants placed
on being able to check who has accessed their medical
record for purposes other than clinical care, this should
also be considered. Both of these could be accommodated
through a secure web-based portal that patients can use to
access their health record, a technology that is gaining
considerable attention [22-24].
We noted earlier that dialogue participants expressed con-
cern over what happens to one's personal information
once it is released to researchers – regardless of whether
initial consent for the release of the information to the
researcher was required. This highlights the importance of
having trustworthy accountable systems for managing
data. In part, this is a matter of ensuring that adequate
access and security controls are in place in research facili-
ties. Recent reports of lost or stolen health information
involving negligence with regard to basic safeguards can
readily undermine public confidence [25-28]. Regarding
external accountability, in Canada, provincial informa-
tion and privacy commissioners/ombudsmen currently
have the authority to audit the practices of institutions
that manage personal data. For practical reasons, this is
usually a complaint-driven system. For larger data insti-
tutes, it is common practice to apprise these commission-
ers' offices of their data management practices in the
absence of any complaint. Ideally, similar reporting sys-
tems should be in place for universities with smaller,
more heterogeneous, data holdings. A practicable and
meaningful reporting system remains an outstanding
challenge for the research community.
Participants in our dialogues were largely unaware of the
research process – particularly the ethic review process.
For some, this raised concerns over the process. They also
generally had difficulty articulating what it was about the
commercial element to research that would cause them to
desire greater control over use of their personal informa-
tion when there was a profit element. Researchers and
policy makers should continue to engage the public to
promote greater public understanding of the research
process – in particular, the public-private interface and the
role of research ethics boards – and to better understand
themselves how to best to respond to any concerns they
may have. We should also continue to look for feasible
alternatives to existing approaches to consent for observa-
tional research, when some form of consent is required.
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